FDA approves Blueprint’s AYVAKIT for gastrointestinal cancer
AYVAKIT marks the first precision therapy to be approved by the FDA to treat a genomically defined population…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
10 Jan 20
AYVAKIT marks the first precision therapy to be approved by the FDA to treat a genomically defined population…
09 Jan 20
FDA has approved KEYTRUDA based on data from KEYNOTE-057, a multicentre, open-label, single-arm trial, involving 96 patients
07 Jan 20
In the Phase III DAPA-HF trial, Farxiga has reduced the incidence of the composite outcome of CV death…
20 Dec 19
Ervebo is now the first FDA-approved vaccine for Ebola and is indicated to be used in people aged…
18 Dec 19
Lynparza is a PARP inhibitor that blocks DNA damage response (DDR) in tumour cells and leads to the…
17 Dec 19
XTANDI is an androgen receptor inhibitor intended for treating castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer
16 Dec 19
If approved, the new formulation of DTG is expected to be the first integrase inhibitor offered as a…
13 Dec 19
Pfizer has subjected its XELJANZ to more than 50 clinical trials across the world, of which more than…
Zip Health will offer the same range of prescription drugs online as its UK equivalent - once the…
12 Dec 19
KTE-X19 is an investigational, autologous, anti-CD19 CAR T cell therapy that uses the XLP manufacturing process